The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. - Université de Lille Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2022
Fichier non déposé

Dates et versions

hal-04382585 , version 1 (09-01-2024)

Identifiants

Citer

Marion Panhaleux, David Launay, Nicolas Penel, Olivier Lambotte, Alexandra Forestier. The letter responds to comment on: Anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study.. European Journal of Cancer, 2022, European Journal of Cancer, ⟨10.1016/j.ejca.2022.01.021⟩. ⟨hal-04382585⟩

Collections

UNIV-LILLE
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More